BioInvent Q3 2023: One Step Forward on the Road to Partnering with BI-1808 - Redeye

Redeye comments on the third quarter report of BioInvent. All projects are progressing. Importantly, BI-1808 is the second program, after BI-1206, to advance into phase II. The subcutaneous version of BI-1206 is being studied with results expected by H1 2024 in lymphoma.

Länk till analysen i sin helhet: https://www.redeye.se/research/951132/bioinvent-q3-2023-one-step-forward-on-the-road-to-partnering-with-bi-1808?utm_source=finwire&utm_medium=RSS